▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2436 by analyst upside · 2026-11-14
NBIX
Neurocrine Biosciences, Inc.
Healthcare · Market Cap $17B · P/E 25.1x
ANALYST PRICE TARGET
+24.3%
implied upside to consensus target
Current Price $167.4
Consensus Target $208.11
Bull Target $253.0
Bear Target $150.0
Analysts Covering 28
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
20
Hold
4
Sell
0
52-Week Low $122.14
52-Week High $186.12
YTD Return +19.1%
FUNDAMENTALS
Market Cap $17B
P/E Ratio (TTM) 25.1x
Forward P/E 13.6x
EPS (TTM) $6.66
PEG Ratio 0.33
Dividend Yield N/A
Revenue (TTM) $3.7B
Profit Margin 19.0%
52-WEEK RANGE
52-Week Low $122.14
52-Week High $186.12
Current Price $167.4
Bear Target $150.0
Bull Target $253.0
● Now $167.4 ● Target $208.11
TRADING DATA
Avg Volume 1.3M
YTD Return +19.1%
Analyst Count 28
Consensus Buy
Upside to Target +24.3%
Last Updated 2026-11-14

ANALYST SUMMARY

Neurocrine Biosciences, Inc. (NBIX) is currently trading at $167.4 with a Wall Street consensus price target of $208.11, implying potential upside of 24.3% over the next 12 months. 28 analysts currently cover NBIX, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $253.0, while the most cautious has a target of $150.0.

NBIX operates in the Healthcare sector with a market capitalisation of $17B. The stock is up 19.1% year-to-date and is currently trading near the upper end of its 52-week range of $122.14 – $186.12.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

EHC +10.7%
Encompass Health Corporation
$14B · P/E 22.6x · Buy
COO +5.0%
The Cooper Companies, Inc.
$12B · P/E 21.4x · Hold
ALNY +81.8%
Alnylam Pharmaceuticals, Inc.
$22B · P/E 7.9x · Buy
ALGN +10.4%
Align Technology, Inc.
$12B · P/E 24.4x · Buy
DVA +27.3%
DaVita Inc.
$11B · P/E 13.2x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for NBIX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim - Reiterated
Buy → Buy 2026-11-04 62% win rate (8 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-11-03 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-11-03 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-11-03 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-11-03 14% win rate (7 calls)
Needham reit
Buy → Buy 2026-10-16 20% win rate (5 calls)
BMO Capital - Reiterated
Market Perform → Market Perform 2026-10-12 Building track record
UBS - Reiterated
Buy → Buy 2026-09-29 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
26/30
Consensus clarity
18/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →